Entrada Therapeutics, Inc.

NASDAQ:TRDA

Biotechnology

Healthcare
$5.03 +0.37%

+$0.03 today

Market cap
$196.93M
Beta
-0.26
P/E (TTM)
-1.7
EPS (TTM)
-$3.97
52W Low $4.93High $16.45

Volume 0.82M

Average 0.36M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$128.51M

FY 2025 · Annual

Investing Cash Flow

$116.81M

FY 2025 · Annual

Financing Cash Flow

$887,000.00

FY 2025 · Annual

-99.1% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(51.16M)(94.62M)(6.69M)65.63M(143.75M)
Depreciation & Amortization1.12M1.9M2.84M3.77M4.1M
Deferred Income Tax00000
Stock-Based Compensation2.53M9.9M13.11M17.92M19.61M
Change in Working Capital(3.42M)(11.11M)136.32M(118.85M)(4.8M)
Accounts Receivables0002.2M2.5M
Inventory00000
Accounts Payables(715K)5.29M(2.81M)991K(1.8M)
Other Working Capital(2.71M)(16.4M)139.12M(122.04M)(5.5M)
Other Non-Cash Items74K151K(5.78M)(10.02M)(3.67M)
Operating Cash Flow(50.86M)(93.79M)139.8M(41.56M)(128.51M)
Capital Expenditures(4.58M)(2.89M)(5.61M)(3.16M)(1.04M)
Acquisitions (Net)00000
Purchases of Investments0(221.98M)(407.21M)(437.72M)(141.61M)
Sales of Investments076.21M274.43M413.08M259.46M
Other Investing Activities00000
Investing Cash Flow(4.58M)(148.65M)(138.4M)(27.8M)116.81M
Debt Repayment00000
Common Stock Issued190.69M479K19.41M99.61M887K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities939K01.63M3.36M0
Financing Cash Flow307.46M479K21.04M102.96M887K
Effect of Forex Changes0(3.95M)000
Net Change in Cash252.02M(245.91M)22.45M33.61M(10.82M)
Free Cash Flow(55.44M)(96.67M)134.19M(44.72M)(129.55M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$143.8M
+ D&A$4.1M
+ Stock-Based Comp$19.6M
+ Deferred Tax$0
- Working Capital-$4.8M
- Other Non-Cash-$3.7M
= Operating Cash Flow-$128.5M
- Capex-$1.0M
= Free Cash Flow-$129.6M

Analysis

FY2025 free cash flow is -$129.6M. FCF conversion is 90.1% of net income. Operating cash flow was -$128.5M, with capex of -$1.0M. The largest bridge item is Stock-Based Comp at $19.6M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 5, 2026
8-KCurrent reportOct 14, 2026
SC 13D/ASC 13D/A filingSep 10, 2026
4Statement of changes in beneficial ownershipSep 9, 2026

Does TRDA generate free cash flow?

Entrada Therapeutics, Inc. (TRDA) generated -$129.55M of free cash flow in fiscal 2025.

How much operating cash flow does TRDA produce?

Operating cash flow was -$128.51M, before capital expenditures of $1.04M.